Analytical Data
-
Gene name
SCD
- Application
-
Alternative Names
SCD；FADS5；SCD1；SCDOS；Stearoyl-CoA desaturase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O00767
-
Expression Region
1-359aa
-
AA Sequence
MPAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRPDIKDDIYDPTYKDKEGPSPKVEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGAHRLWSHRSYKARLPLRLFLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGSTLDLSDLEAEKLVMFQRRYYKPGLLMMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSAAHLFGYRPYDKNISPRENILVSLGAVGEGFHNYHHSFPYDYSASEYRWHINFTTFFIDCMAALGLAYDRKKVSKAAILARIKRTGDGNYKSG
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Sickle Cell Disease (SCD) is a hereditary blood disorder characterized by the mutation of the beta-globin gene, leading to the production of abnormal hemoglobin known as hemoglobin S (HbS). This mutation causes red blood cells to adopt a rigid, sickle shape, resulting in various complications such as pain crises, anemia, and increased risk of infection. The complexity of SCD has spurred extensive research into potential treatments, including gene therapy and pharmacological approaches. One promising area of investigation involves the use of recombinant proteins, particularly modified versions of hemoglobin, that aim to alleviate the clinical symptoms associated with sickle cell pathology. Researchers focus on developing these recombinant proteins to enhance oxygen transport, reduce hemolysis, and improve the overall rheological properties of the blood. Additionally, advancements in protein engineering and expression systems have enabled the production of safer and more effective therapeutic agents. Through a multidisciplinary approach involving molecular biology, biochemistry, and medicine, the exploration of SCD recombinant proteins holds the potential to transform the management of this debilitating disorder, offering hope for improved patient outcomes and quality of life.
